Kornimate/medical-research-clean huggingface dataset:
efficacy of conservative treatments for urinary incontinence in women

Conditions: Urinary Incontinence

Summary: to conduct a retrospective study to examine the effect of these conservative treatments to the symptoms and quality of life of patients with urinary incontinence. the investigators will use both subjective and objective assessment parameters, such as self-report symptoms, bladder diary, pad test and urodynamic study to access the improvement.

urinary incontinence is a common problem among women. the main types include stress incontinence, urge incontinence, and overflow incontinence. other underlying pathology, such as cancer or neurologic disease can also cause urinary incontinence. to limit the medical expenses and possible complications of surgical treatment, the current treatment guidelines recommend conservative treatment as the first choice. according to american urological association (aua)/society of urodynamics, female pelvic medicine \& urogenital reconstruction (sufu) guidelines, the first-line treatment for non-neurologic overactive bladder should be behavioral therapy, such as bladder training, water restriction, and pelvic floor muscle training, physiological feedback, pessary, etc. bladder training aims to increase the time interval between voids, and to increase the bladder capacity by self-adjusted schedules. pelvic floor muscle training strengthens the pelvic floor muscles to provide urethral support to prevent urine leakage and suppress urgency. there is strong evidence that pelvic floor muscle training is beneficial for stress urinary incontinence. the second-line treatment is medication, including anticholinergic drugs and ß3 adrenoceptor-acting agents. anticholinergic drugs can reduce bladder detrusor contraction, and ß3 adrenoceptor-acting agents can relax the detrusor and increase bladder capacity.

Eligibility criteria:
inclusion criteria: * adult female patient diagnosed with urinary incontinence through clinical assessment * diagnosed at mackay memorial hospital and underwent non-surgical treatment and subsequent follow-up. exclusion criteria: * choosing invasive or surgical treatment options (such as bladder botulinum toxin injection, urethral sling surgery). * unable to comply with regular follow-up for at least one year. * pregnant women * patients with a history of neuromuscular disorders.
study of crenolanib vs midostaurin following induction chemotherapy and consolidation therapy in newly diagnosed flt3 mutated aml

Conditions: Newly Diagnosed FLT3 Mutated AML

Summary: a phase iii randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed aml subjects with flt3 mutation. about 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of aml (chemotherapy and if eligible, transplantation) (arm a) or midostaurin and standard treatment (arm b). potentially eligible subjects will be registered and tested for the presence of flt3 mutation. once the flt3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of de novo aml according to world health organization (who) 2016 classification * presence of flt3-itd and/or d835 mutation(s) in bone marrow or peripheral blood * age ≥ 18 years and ≤ 60 years * adequate hepatic function within 48 hours prior to induction chemotherapy * adequate renal functions within 48 hours prior to induction chemotherapy * ecog performance status within 48 hours prior to induction chemotherapy ≤ 3 * eligible for intensive cytarabine/daunorubicin (7+3) chemotherapy specified exclusion criteria: * acute promyelocytic leukemia (apl) * known clinically active central nervous system (cns) leukemia * severe liver disease * active infections * known, active infection with hepatitis b virus (hbv) or hepatitis c virus (hcv) * known infection with human immunodeficiency virus (hiv) * prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)
prospective analysis of changes in background parenchymal enhancement (bpe) and amount of fibroglandular tissue on breast mri

Conditions: Breast Cancer

Summary: tamoxifen is a hormonal treatment for breast cancer. it prevents recurrent disease and decreases death. tamoxifen is given to women with and at high risk for breast cancer. these women also commonly have breast mri to monitor for breast cancer. some features of normal breast tissue visible on breast mri change depending on patient hormonal status. it has been questioned if hormonal changes due to tamoxifen are seen on breast mri. pilot data suggests this is true. if tamoxifen causes changes in normal breast tissue on mri, more study could be done looking at whether breast mri could tell us anything about whether tamoxifen is working. this study is being done to see if tamoxifen changes normal breast tissue on mri. it will also look at if other factors like taking anti-depressants or gene type have any effect.


Eligibility criteria:
inclusion criteria: * females with stage 0-3 breast cancer who have had or are planned to have a breast mri within 1 year prior to starting tamoxifen * premenopausal status is defined as intact ovaries and still menstruating * clinical and mri follow-up planned at mskcc or mckcc regional facility * willing and able to undergo all study procedures exclusion criteria: * contraindication to breast mri (such as non-compatible cardiac pacemakers or intracranial vascular clips, allergy to gadolinium) * bilateral breast cancer or treatment such as: * history of or planned bilateral breast irradiation * history of or planned bilateral mastectomy * bilateral breast cancer * history of unilateral mastectomy or radiation treatment with contralateral breast cancer * taking chemo- or hormonal therapy at the time of the baseline breast mri * estrogen and progesterone receptor negative breast cancer * gfr less than gfr \< 30 ml/min/1.73m2 * postmenopausal women * pregnant and/or nursing women * less than 21 years of age

Keywords: fibroglandular tissue tamoxifen mri background parenchymal enhancement 10-217
a multicenter study evaluating the effectiveness of endo.angel in improving the quality of colonoscopy

Conditions: Adenoma Detection Rate

Summary: colonoscopy is a key technique in the detection and diagnosis of lower gastrointestinal diseases. high quality endoscopy results in better disease outcomes. however, the operant level of different endoscopists is significantly different.this study aims to construct a real-time quality monitoring system based on computer vision, named endo.angel, which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.

this study aims to construct a real-time quality monitoring system based on computer vision, named endo.angel, which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.criteria for inclusion and exclusion are determined prior to endoscopic examination. candidates who meet all inclusion criteria as well as do not meet all exclusion criteria are bring into the study. participants randomized before the examination, they are divided into the exposed group assisted by endo.angel or the non-exposed group without endo.angel. followup are conducted after the examination.study will be finished when all followup is done,and the examination result collected from participants will send to an independent review data analysis group.

Eligibility criteria:
inclusion criteria: 1. male or female aged 18 years or above; 2. colonoscopy is needed to further characterize gastrointestinal diseases; 3. ability to read, understand and sign informed consent forms; 4. the researchers believe that the subjects can understand the process of the clinical study and are willing and able to complete all the study procedures and follow-up visits to cooperate with the study procedures. exclusion criteria: 1. participated in other clinical trials, signed informed consent forms and followed up in other clinical trials. 2. participate in a drug clinical trial and during the elution period of the trial or control drug 3. drug or alcohol abuse or mental disorder in the last 5 years; 4. pregnant or lactating women; 5. patients with multiple polyp syndrome; 6. patients with known space-occupying tumor or intestinal stenosis; 7. patients with known perforation or colonic obstruction; 8. a history of anaphylaxis with antispasmodic has been documented; 9. the researchers did not consider the subjects suitable for colonoscopy; 10. the researchers determined that the subjects had high-risk diseases or other special conditions that were not appropriate for clinical trials.

Keywords: colonoscopy computer vision adenoma detection rate endo.angel
18fdg-pet in patients with melanoma or nsclc treated with immunotherapy

Conditions: Melanoma; NSCLC; Positron-Emission Tomography; Immunotherapy; 18F-FDG

Summary: study the efs and os according to 18fdg pet in patients with melanoma or non small cell lung cancer treated by immunotherapy.

study efs in patients with melanoma or nsclc treated by immunotherapy (anti ctla4 or anti pdl1) and performed18fdg pet multicentric retrospective study

Eligibility criteria:
inclusion criteria: * patients treated for melanoma or nsclc with immunotherapy (anti ctla4 or antipdl1) * patients treated in brest, morlaix, landerneau hospital * patients performed fdg pet * no opposition to study exclusion criteria: * age under 18 years old * refusal to participate

Keywords: melanoma nsclc fdg pet immunotherapy
phenotyping genetic risk for type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Genetics

Summary: this study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.

the study team will recruit individuals based on genetic risk score for type 2 diabetes from the biobank populations who have agreed to be recontacted for future research. each participant will undergo a frequently sampled four-hour oral glucose tolerance test and whole body dxa scan (dual-energy x-ray absorptiometry) in addition to baseline laboratory and history assessment.

Eligibility criteria:
inclusion criteria: * age 10-70 years * prior participant of the upenn biobank or center for applied genomics biobank and agreed to be recontacted for future research. * adults with bmi 25kg/m2 or higher, children and adolescents with bmi 85th percentile or higher exclusion criteria: * prior diagnosis of type 1, type 2, or secondary diabetes * use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication * acute illness that may impact insulin and glucose dynamics * pregnancy * hypothalamic obesity or related genetic disorder of metabolism * recent systemic chemotherapy use * gastrointestinal impairment or surgery that may impact absorption * anemia * major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult * inability to comply with study protocol

Keywords: polygenic risk for type 2 diabetes
castro1 - study on crp apheresis after ischemic stroke

Conditions: Stroke, Ischemic

Summary: castro1 is a study to investigate the reduction of c-reactive protein (crp) by therapeutic apheresis (crp-apheresis) in patients after primary treatment of ischemic stroke. the term therapeutic apheresis commonly refers to medical procedures, where pathogenic constituents are being removed from the circulating blood. elimination is performed by adsorbers outside the body in an extracorporeal circulation. for removal of the pathogenic substances the plasma is separated from the blood (circulation) to pass the adsorber. the purified plasma is merged with the solid blood components thereafter and returned to the patient. the adsorber "pentrasorb® crp" used for crp apheresis is ce-certified. it is designated to the selective depletion of c-reactive protein from human blood.

the purpose of the study is to evaluate the safety and efficacy of crp apheresis in patients following ischemic stroke. crp apheresis is to be conducted with the aim of reducing cerebral damage following the guideline-appropriate primary therapy of ischemic stroke. a possible protective effect of crp apheresis will be assessed by clinical scores, laboratory determination of immunologic parameters and determination of the size of the infarct area by magnetic resonance imaging (mri). the study will be randomized, controlled and monocentric.

Eligibility criteria:
inclusion criteria: * ischaemic stroke with determination of infarct size by imaging (mri) * nihss 1-24 * crp increase ≥ 5 mg/l within presumed 72 hours after stroke and/or crp value \> 10 mg/l * written informed consent of the patient or his legal representative exclusion criteria: * age \< 18 years * severe dysphagia (danger of aspiration pneumonia) * clinical or laboratory evidence of a severe systemic infection * participation in other interventional studies * contraindications against apheresis therapy * modified rankin scale (mrs) before index event ≥ 3 * intracranial hemorrhage * epileptic seizure in the context of the acute event * pregnancy, lactation
selective subarachnoid anesthesia. comparison of hyperbaric bupivacaine and hyperbaric prilocaine

Conditions: Knee Arthroscopy (for Diagnostic or Therapy); Inguinal Hernia Repair (Not Urgent)

Summary: selective spinal anesthesia is widely used for ambulatory surgery. unilateral spinal anesthesia is a suitable option for ambulatory anesthesia as it is efficient and effective. lidocaine has been the well-known choice for this procedure. however, it is associated to transient neurologic symptoms (tns). different anesthetic strategies for this procedure have been performed, for example, the use of small doses of long-acting agents and the use of additives such as opioids. the ideal local anesthetic should be lidocaine-like without risk of transient neurologic symptoms. we design and plan a randomised clinical trial to show if hyperbaric prilocaine 2% would be an alternative.


Eligibility criteria:
inclusion criteria: * patients with a scheduled knee arthroscopy * patients with a scheduled inguinal hernioplasty exclusion criteria: * patient refusal to regional anesthesia * american society of anesthesiologists score risk equal or greater than 4 * body mass index greater than 32 * coagulopathy * cutaneous infection at injection site
pharmacogenomic study of androgenetic alopecia

Conditions: Androgenetic Alopecia

Summary: androgenic alopecia, the common form of hair loss is a highly heritable disorder of considerable social significance affecting around 40% of adult men and women. a variety of genetic and environmental factors are likely to play a role in androgenetic alopecia. genetic variants in the human androgen receptor gene (ar) have been reported to be associated with aga in caucasians. other genes involved with hair loss also have been found. one of them being a gene on chromosome 3 (3q26). a recent genome-wide association study in 296 individuals with male-pattern baldness and 347 controls had carried out and five snps on chromosome 20p11 were found to be highly significant association for aga (rs2180439 combined p = 2.7 x 10(-15)). no interaction was detected with the x-chromosomal androgen receptor locus, suggesting that the 20p11 locus has a role in a yet-to-be-identified androgen-independent pathway. the total number of evaluated patients with androgenic alopecia will be at least 300. all patients will be further grouped as good responders or poor responders to conventional medications, such as topical minoxidil and systemic finasteride. candidate genes potentially involved in gout and its treatment response will be selected from the published literatures; specifically, two resources of candidate genes will be selected: (i) genes which are known to directly link with androgenic alopecia, and (ii) genes are potentially implicated in particular pathways of androgen/estrogen receptors, metabolism and downstream signals, and genes involved in anti-oxidants or hair growth. the snp genotyping will be performed by maldi-tof mass spectrometry. data analysis will be performed by comparing snps allele frequency between good responder and poor responder to conventional medications of patients with androgenic alopecia and further comparing to the allele frequency of snps in healthy controls. a functional study will also be done to prove the genetic association.


Eligibility criteria:
inclusion criteria: * willing to sign inform consent form * willing to received history taking by telephone or interview * diagnosed androgenetic alopecia by hamilton-norwood classification * more than 20 year-old, both sex exclusion criteria: * ever had trauma over alopecia area * cancer, infection, or other systemic disease that might interfere diagnosis * unconfirmed diagnosis clinically or pathologically.

Keywords: genetic susceptibility of androgenetic alopecia genetic difference in finasteride response
intraoperative fluid therapy for deceased donor renal transplantation

Conditions: Kidney Failure

Summary: delayed graft function (dgf) is defined as requirement for dialysis in the first week following kidney transplantation. dgf is a common complication occurring in 39% of the deceased donor renal transplants at the investigators' institution with significant cost and outcome implications. the 3 major risk factors for dgf are donor graft characteristics, recipient factors and perioperative management. the most easily modifiable of these factors is perioperative management, in particular intraoperative fluid therapy. the investigators propose to compare the amount of fluid administered using the current standard of care with the fluid administered when optimizing the cardiac output (co) using esophageal doppler monitoring (edm) to guide fluid therapy. edm measures blood flow in the descending aorta, optimizing stroke volume (sv) and cardiac output (co) by indicating when fluid administration fails to produce an increase in co.


Eligibility criteria:
inclusion criteria: * age greater than 18 years * signed informed consent * listed for deceased donor transplantation. exclusion criteria: * esophageal surgery or cancer * esophageal stricture, varices or diverticulum * upper airway surgery * coarctation of the aorta * significant valvular heart disease * clinically significant cardiac arrhythmias * patient randomized to other trials with an outcome variable of delayed graft function or early graft function will also be excluded
sternal ecg patch comparison trial

Conditions: Syncope; Presyncope; Palpitations; Atrial Fibrillation; Supraventricular Tachycardia

Summary: this study is intended to compare the new carnation ambulatory monitoring (cam) system, a patch monitoring system, with the holter monitoring system. holters represent the current standard for continuous recording of the ecg over extended periods.

the purpose of this research is to simplify the system of recording ecgs. carnation ambulatory monitoring (cam) system is a small patch system that can be worn during most activities include showering. each patient will be his or her own control, and will wear the cam and holter systems simultaneously for 24 hours. both systems will then be sent out for analysis.

Eligibility criteria:
inclusion criteria: * syncope of uncertain etiology or * pre-syncope of uncertain etiology or * palpitations of uncertain etiology or * management of known af/svt patients exclusion criteria: * any dermatitis or infected skin over the sternum (carnation patch) or left upper anterior thorax (zio patch). * a sternal or thoracic incision that extends under the patch within 3 months from the date of enrollment
legume diet satiety pilot study

Conditions: Obesity; Colorectal Carcinoma

Summary: this pilot study is designed to test the effects of a high legume (dried bean) diet on hunger and other indicators of health over the course of eight weeks, compared to a more conventional healthy diet.

the goal of the currently proposed study is to conduct a randomized controlled feeding pilot study within a more diverse population also at high risk for colorectal carcinoma (crc) to evaluate whether a high-legume diet will result in increased satiety and in turn will facilitate reduced energy intake and weight loss compared to a control diet provided under similar conditions. in addition, explore potential beneficial effects of the high-legume diet on gastric emptying and circulating levels of appetite-regulating hormones and other biomarkers. dietary behaviors that are even moderately more satiating over time have the potential to enhance weight loss and could lead to a significant public health impact among populations at high risk for colorectal carcinoma (crc) and other chronic diseases. towards the end of the study, the participants will do an additional test, looking at how long food takes to pass through the digestive system using a smartpill capsule. the smartpill is a pill about the size of a large multivitamin that can measure ph, pressure, and temperature changes, which it uses to assess where in the digestive tract it is. the participant swallows the pill, and carries around a receiver that is about the size of a deck of cards for the next 3-5 days. the smartpill is expelled, and the receiver notifies the participant that they can return the receiver to the study personnel.

Eligibility criteria:
inclusion criteria: * bmi overweight-obese: 25.0-40 kg/m2 * colonoscopy within the last two years that found ≥1 adenoma * english speaking * ambulatory, able to come to either food distribution site to pick up food and participate in clinical examinations and laboratory tests exclusion criteria: * serious medical condition (e.g., cancer, heart disease, kidney disease, diabetes) * history of crc, bowel resection, polyposis syndrome, or inflammatory bowel disease * smoked regularly in the past year * dietary restrictions substantially limiting compliance or vegetarian or vegan diet * planning on changing diet or exercise behavior in the next 6 months * regular use of medication that may alter inflammation markers, insulin, glucose, or gut function (i.e. regular use of non-steroidal anti-inflammatory medication, insulin therapy, steroid therapy, or antibiotics)

Keywords: weight loss epidemiology nutrition